Payment overview · 2025
General Payments
$238.25
13 reported records · 6 companies
Healthcare provider profile · identity verified
Jeffrey S Lambert, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TUCSON, AZ · NPI 1578762134
Verified facts
What the public records show
CMS Open Payments records show Jeffrey S Lambert, M.D. received $238.25 in general payments during 2025 across 13 reported records.
Merck Sharp & Dohme LLC accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Prolia by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $56.11 | 23.6% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $46.27 | 19.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.83 | 19.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.94 | 15.9% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $35.40 | 14.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.70 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.25 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $56.11 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $56.11 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $46.27 | 3 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $35.40 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
44 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 374 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 357 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 112 |
| Lisinopril | Lisinopril | 312 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 264 | 79 |
| Losartan Potassium | Losartan Potassium | 155 | 47 |
| Metformin Hcl | Metformin Hcl | 148 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 35 |
| Famotidine | Famotidine | 112 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 32 |
| Simvastatin | Simvastatin | 100 | 33 |
| Alendronate Sodium | Alendronate Sodium | 90 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 27 |
| Gabapentin | Gabapentin | 83 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 23 |
| Omeprazole | Omeprazole | 83 | 27 |
| Alprazolam | Alprazolam | 79 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 22 |
| Furosemide | Furosemide | 57 | 18 |
| Allopurinol | Allopurinol | 55 | 18 |
| Trazodone Hcl | Trazodone Hcl | 55 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 30 |
| Potassium Chloride | Potassium Chloride | 48 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 13 |
| Finasteride | Finasteride | 45 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 11 |
| Prolia | Denosumab | 44 | 27 |
| Montelukast Sodium | Montelukast Sodium | 43 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 14 |
| Glipizide | Glipizide | 41 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Lovastatin | Lovastatin | 34 | 11 |
| Carvedilol | Carvedilol | 33 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 13 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | 11 |
| Atenolol | Atenolol | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $238.25 · 13 records | Merck Sharp & Dohme LLC | ABRYSVO, AREXVY, CAPVAXIVE, COMIRNATY, EVENITY, GARDASIL 9, LIBTAYO, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, TZIELD | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error